JP2006528701A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006528701A5 JP2006528701A5 JP2006533316A JP2006533316A JP2006528701A5 JP 2006528701 A5 JP2006528701 A5 JP 2006528701A5 JP 2006533316 A JP2006533316 A JP 2006533316A JP 2006533316 A JP2006533316 A JP 2006533316A JP 2006528701 A5 JP2006528701 A5 JP 2006528701A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- medicinal composition
- disease
- independently
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 93
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 210000002966 serum Anatomy 0.000 claims description 17
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 claims description 15
- HCZKYJDFEPMADG-UHFFFAOYSA-N nordihydroguaiaretic acid Chemical compound C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000004423 acyloxy group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 235000021588 free fatty acids Nutrition 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 150000005830 nonesterified fatty acids Chemical class 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000000044 Amnesia Diseases 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 3
- 208000031091 Amnestic disease Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 230000006986 amnesia Effects 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- 208000020016 psychiatric disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims 16
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 3
- 102000040945 Transcription factor Human genes 0.000 claims 2
- 108091023040 Transcription factor Proteins 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000010370 Adenoviridae Infections Diseases 0.000 claims 1
- 206010060931 Adenovirus infection Diseases 0.000 claims 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 206010023163 JC virus infection Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009608 Papillomavirus Infections Diseases 0.000 claims 1
- 208000008071 Parvoviridae Infections Diseases 0.000 claims 1
- 206010057343 Parvovirus infection Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000005181 Varicella Zoster Virus Infection Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 239000001273 butane Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007914 intraventricular administration Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 210000000274 microglia Anatomy 0.000 claims 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 claims 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims 1
- 239000002953 phosphate buffered saline Substances 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000010531 varicella zoster infection Diseases 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 0 *C(Cc1cc(*)c(*)cc1)C(*)Cc1ccc(*)c(*)c1 Chemical compound *C(Cc1cc(*)c(*)cc1)C(*)Cc1ccc(*)c(*)c1 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 5
- ORQFDHFZSMXRLM-UHFFFAOYSA-N 4-[4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene Chemical compound C1=C(OC)C(OC)=CC=C1CC(C)C(C)CC1=CC=C(OC)C(OC)=C1 ORQFDHFZSMXRLM-UHFFFAOYSA-N 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 208000037905 systemic hypertension Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47200803P | 2003-05-20 | 2003-05-20 | |
| US47218803P | 2003-05-20 | 2003-05-20 | |
| US47228203P | 2003-05-20 | 2003-05-20 | |
| US47214403P | 2003-05-20 | 2003-05-20 | |
| US47229903P | 2003-05-20 | 2003-05-20 | |
| PCT/US2004/016117 WO2004112696A2 (en) | 2003-05-20 | 2004-05-20 | Methods and compositions for delivery of catecholic butanes for treatment of diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006528701A JP2006528701A (ja) | 2006-12-21 |
| JP2006528701A5 true JP2006528701A5 (enExample) | 2007-07-12 |
Family
ID=33545640
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533314A Pending JP2006528700A (ja) | 2003-05-20 | 2004-05-20 | 肥満の治療のためのカテコールブタンの投与のための方法と組成物 |
| JP2006533316A Pending JP2006528701A (ja) | 2003-05-20 | 2004-05-20 | 疾患の治療のためのカテコールブタンの投与のための方法と組成物 |
| JP2006533343A Pending JP2007500229A (ja) | 2003-05-20 | 2004-05-20 | 腫瘍の治療のためのカテコールブタンの投与のための方法と組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533314A Pending JP2006528700A (ja) | 2003-05-20 | 2004-05-20 | 肥満の治療のためのカテコールブタンの投与のための方法と組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006533343A Pending JP2007500229A (ja) | 2003-05-20 | 2004-05-20 | 腫瘍の治療のためのカテコールブタンの投与のための方法と組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060141047A1 (enExample) |
| EP (3) | EP1631271A4 (enExample) |
| JP (3) | JP2006528700A (enExample) |
| CN (1) | CN103585136A (enExample) |
| AU (3) | AU2004249124A1 (enExample) |
| WO (3) | WO2004112695A2 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10214983A1 (de) | 2002-04-04 | 2004-04-08 | TransMIT Gesellschaft für Technologietransfer mbH | Vernebelbare Liposomen und ihre Verwendung zur pulmonalen Applikation von Wirkstoffen |
| EP1540944A1 (en) * | 2002-09-09 | 2005-06-15 | Koninklijke Philips Electronics N.V. | Method of signal reconstruction, imaging device and computer program product |
| WO2006079021A2 (en) * | 2005-01-20 | 2006-07-27 | Sirtris Pharmaceuticals, Inc. | Use of sirtuin-activating compounds for treating flushing and drug induced weight gain |
| ES2606332T3 (es) * | 2005-01-27 | 2017-03-23 | Erimos Pharmaceuticals Llc | Formulaciones orales para la administración de butanos catecólicos incluyendo compuestos de NDGA |
| ATE544444T1 (de) * | 2005-10-11 | 2012-02-15 | Yissum Res Dev Co | Zusammensetzungen für die nasale abgabe |
| US20070128289A1 (en) * | 2005-12-07 | 2007-06-07 | Zhao Jonathon Z | Nano-and/or micro-particulate formulations for local injection-based treatment of vascular diseases |
| FR2896694A1 (fr) | 2006-01-30 | 2007-08-03 | Genfit S A | Utilisation d'inhibiteurs de 15-lipoxygenases dans le traitement du syndrome metabolique |
| US7863157B2 (en) * | 2006-03-17 | 2011-01-04 | Silicon Genesis Corporation | Method and structure for fabricating solar cells using a layer transfer process |
| DE102006013531A1 (de) * | 2006-03-24 | 2007-09-27 | Lts Lohmann Therapie-Systeme Ag | Polylactid-Nanopartikel |
| GB2441499B (en) * | 2006-09-08 | 2011-09-14 | Jasin El Sammadoni | Slimming Spray |
| US9067875B2 (en) | 2006-10-02 | 2015-06-30 | Erimos Pharmaceuticals Llc | Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| EP2076252B1 (en) | 2006-10-02 | 2014-04-02 | Erimos Pharmaceuticals LLC | Tetra-substituted ndga derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
| EP1970051A1 (en) * | 2007-03-14 | 2008-09-17 | Merz Pharma GmbH & Co.KGaA | Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases |
| EP2039352A1 (en) * | 2007-09-18 | 2009-03-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Aqueous-core lipid nanocapsules for encapsulating hydrophilic and/or lipophilic molecules |
| US8962015B2 (en) | 2007-09-28 | 2015-02-24 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| US20100080773A1 (en) | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
| US9145453B2 (en) * | 2007-09-28 | 2015-09-29 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| US8846053B2 (en) * | 2008-09-26 | 2014-09-30 | Sdg, Inc. | Orally bioavailable lipid-based constructs |
| US9161943B2 (en) | 2007-12-31 | 2015-10-20 | Industrial Technology Research Institute | Sustained release composition and manufacturing method thereof |
| US20100093872A1 (en) * | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
| WO2010102066A1 (en) | 2009-03-05 | 2010-09-10 | Bend Research, Inc. | Dextran polymer powder for inhalation administration of pharmaceuticals |
| EP2411137B1 (en) | 2009-03-27 | 2016-09-07 | Bend Research, Inc. | Spray-drying process |
| DE102009031274A1 (de) * | 2009-06-30 | 2011-01-13 | Justus-Liebig-Universität Giessen | Liposomen zur pulmonalen Applikation |
| WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| US9084944B2 (en) | 2010-09-03 | 2015-07-21 | Bend Research, Inc. | Spray-drying apparatus and methods of using the same |
| PT2611529T (pt) | 2010-09-03 | 2019-05-09 | Bend Res Inc | Método de secagem por pulverização |
| US8815294B2 (en) | 2010-09-03 | 2014-08-26 | Bend Research, Inc. | Pharmaceutical compositions of dextran polymer derivatives and a carrier material |
| JP5222917B2 (ja) * | 2010-09-21 | 2013-06-26 | 財團法人工業技術研究院 | 徐放性組成物およびその製造方法 |
| WO2012040502A1 (en) | 2010-09-24 | 2012-03-29 | Bend Research, Inc. | High-temperature spray drying process and apparatus |
| US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
| US9084727B2 (en) | 2011-05-10 | 2015-07-21 | Bend Research, Inc. | Methods and compositions for maintaining active agents in intra-articular spaces |
| BR112014014262A2 (pt) * | 2011-12-14 | 2017-06-13 | Univ Johns Hopkins | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. |
| WO2014134202A1 (en) * | 2013-02-26 | 2014-09-04 | Triact Therapeutics, Inc. | Cancer therapy |
| US10335500B2 (en) | 2014-05-12 | 2019-07-02 | The Johns Hopkins University | Highly stable biodegradable gene vector platforms for overcoming biological barriers |
| JP6953414B2 (ja) * | 2016-01-20 | 2021-10-27 | フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ | 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法 |
| US11077173B2 (en) | 2017-03-13 | 2021-08-03 | Sdg, Inc. | Lipid-based nanoparticles and methods using same |
| US20210137838A1 (en) | 2017-03-13 | 2021-05-13 | Sdg, Inc. | Lipid-based nanoparticles with enhanced stability |
| WO2020210805A1 (en) | 2019-04-11 | 2020-10-15 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| CN114831938B (zh) * | 2022-05-24 | 2023-04-18 | 郑州大学第一附属医院 | 一种包载阿托伐他汀钙的聚合物胶束、制剂及制备方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3934034A (en) * | 1972-08-21 | 1976-01-20 | Sandoz, Inc. | Hydroxy substituted diphenylalkyls for treatment of lipidemia |
| US4098908A (en) * | 1975-10-20 | 1978-07-04 | Sandoz, Inc. | Phenoxyphenyl pyridyl ketones and derivatives and their use as hypolepidemic agents |
| US5008294A (en) * | 1985-02-11 | 1991-04-16 | Chemex Pharmaceuticals, Inc. | Methods of treating tumors with compositions of catecholic butanes |
| US4774229A (en) * | 1982-04-05 | 1988-09-27 | Chemex Pharmaceuticals, Inc. | Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor |
| US4708964A (en) * | 1984-02-09 | 1987-11-24 | Chemex Pharmaceuticals | Lipoxygenase inhibitors |
| GB8416234D0 (en) * | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
| US4880637A (en) * | 1985-02-11 | 1989-11-14 | Chemex Pharmaceuticals, Inc. | Compositions of catecholic butanes with zinc |
| EP0289506A4 (en) * | 1986-11-19 | 1990-12-12 | Chemex Pharmaceuticals, Inc. | Lipoxygenase inhibitors |
| AU7629694A (en) * | 1993-08-17 | 1995-03-14 | Schering-Plough Healthcare Products, Inc. | Compositions for treating corns, calluses and warts |
| US6365787B1 (en) * | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
| JPH11507038A (ja) * | 1995-06-07 | 1999-06-22 | ユニヴァースティ オブ サザーン カリフォルニア | ５−リポキシゲナーゼ阻害剤を用いる、術後癒着形成を低減又は阻止する方法 |
| US5837252A (en) * | 1996-07-01 | 1998-11-17 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making same |
| US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
| AU8759298A (en) * | 1997-10-06 | 1999-04-27 | Shaman Pharmaceuticals, Inc. | Use of nordihydroguaiaretic acid to lower serum triglycerides, blood pressure and to treat syndrome |
| EP1027045A4 (en) * | 1997-10-31 | 2004-12-08 | Arch Dev Corp | METHODS AND COMPILATIONS FOR REGULATING S-ALPHA REDUCTASE ACTIVITY |
| US6214874B1 (en) * | 1999-10-15 | 2001-04-10 | John Hopkins University | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
| US6608108B2 (en) * | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
| WO2002005825A1 (en) * | 2000-07-13 | 2002-01-24 | Bristol-Myers Squibb Company | Method of modulating microglial activation for the treatment of acute and chronic neurodegenerative disorders |
| US7365099B2 (en) * | 2001-05-31 | 2008-04-29 | Wisconsin Alumni Research Foundation | Animal body fat control |
| HRP20031051B1 (en) * | 2001-06-28 | 2012-01-31 | Pfizer Products Inc. | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion |
| AU2003237379A1 (en) * | 2002-06-10 | 2003-12-22 | Oklahoma Medical Research Foundation | A method for using tethered bis(polyhydroxyphenyls) and o-alkyl derivatives thereof in treating inflammatory conditions of the central nervous system |
-
2004
- 2004-05-20 JP JP2006533314A patent/JP2006528700A/ja active Pending
- 2004-05-20 CN CN201310488557.XA patent/CN103585136A/zh active Pending
- 2004-05-20 EP EP04776086A patent/EP1631271A4/en not_active Ceased
- 2004-05-20 JP JP2006533316A patent/JP2006528701A/ja active Pending
- 2004-05-20 WO PCT/US2004/016114 patent/WO2004112695A2/en not_active Ceased
- 2004-05-20 AU AU2004249124A patent/AU2004249124A1/en not_active Abandoned
- 2004-05-20 WO PCT/US2004/016235 patent/WO2005007080A2/en not_active Ceased
- 2004-05-20 AU AU2004257575A patent/AU2004257575A1/en not_active Abandoned
- 2004-05-20 EP EP04753016A patent/EP1631270A4/en not_active Ceased
- 2004-05-20 EP EP04753013A patent/EP1631269A4/en not_active Withdrawn
- 2004-05-20 AU AU2004249123A patent/AU2004249123A1/en not_active Abandoned
- 2004-05-20 JP JP2006533343A patent/JP2007500229A/ja active Pending
- 2004-05-20 WO PCT/US2004/016117 patent/WO2004112696A2/en not_active Ceased
-
2005
- 2005-11-21 US US11/284,280 patent/US20060141047A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006528701A5 (enExample) | ||
| JP2007500229A5 (enExample) | ||
| TWI689490B (zh) | 用於治療纖維化之經取代之芳族化合物及相關方法 | |
| RU2509076C2 (ru) | Пролекарства нестероидных противовоспалительных средств (nsaia) c очень высокой скоростью проникновения через кожу и мембраны и новые медицинские применения указанных пролекарств | |
| JP2006528700A5 (enExample) | ||
| JP7742226B2 (ja) | 新たな医薬品使用 | |
| JP2010504960A (ja) | 水難溶性カンプトテシン誘導体のサブミクロンナノ粒子及びその製造方法 | |
| JP2010529203A5 (enExample) | ||
| JP2004514663A5 (enExample) | ||
| JP2003535132A (ja) | うっ血性心不全治療用プロスタグランジン化合物 | |
| WO2022122054A1 (zh) | 提高阿霉素肿瘤主动靶向性和肾脏保护的纳米结构脂质制剂及制备方法 | |
| JP2007515439A (ja) | 脂肪蓄積の医学的脂肪分解 | |
| CN102766258A (zh) | 一种白藜芦醇的亲水性结合物及其制备方法和用途 | |
| JP6959246B2 (ja) | 治療に有効な量のジカルボン酸化合物を使用した、病気の予防、治療及び治癒 | |
| Teng et al. | Enhanced the treatment of ischemic stroke through intranasal temperature-sensitive hydrogels of edaravone and borneol inclusion complex | |
| WO2021196659A1 (zh) | 糖基聚醚类化合物脂质体及其制备方法和药物 | |
| JP2023517693A (ja) | 新規ハイドロキノン誘導体 | |
| EP2606883B1 (en) | Uses of n-Butylidenephthalide in Treating a Liver Injury and Improving Liver Function | |
| CN107913261A (zh) | 一种西维来司钠干粉吸入剂及其制备方法 | |
| JP6490597B2 (ja) | 眼の疾患および障害を治療するための方法 | |
| KR20210114962A (ko) | 류코트리엔 수용체 길항제를 함유하는 신규 제제 | |
| JP6480467B2 (ja) | 疎水性薬物送達のための新規なポリマーベースのヒドロトロープ | |
| KR100227541B1 (ko) | 프로스타글란딘 유도체 | |
| JP2007509946A5 (enExample) | ||
| CN106478764B (zh) | 丹参酮iia磷酸衍生物、及其合成和作为药物的应用 |